gen-probe

J.P. Morgan has published a report on Gen-Probe (NASDAQ: GPRO) lowering the price target from $85.00 to $64.00. In the report, J.P. Morgan wrote, "2Q11 results were better than many had feared, in light of the difficult quarter for healthcare utilization-exposed companies (QGEN, DGX, HCA),...

Piper Jaffray continues to believe that Gen-Probe Inc. (NASDAQ: GPRO) enjoys an enviable advantage amongst the new U.S. HPV entrants “with their large installed base of Tigris' that will aid initial account conversions (and believe we have modeled said share shift accordingly).” “That said, we...

J.P. Morgan is out with its report on Gen-Probe (NASDAQ: GPRO), maintaining Overweight. In a note to clients, J.P. Morgan writes, "Data from Gen-Probe's CLEAR pivotal clinical trial for the company's APTIMA HPV test were presented in a symposium on Sunday evening at the EUROGIN meeting. Results...

Morgan Stanley provided color on Gen-Probe's (NASDAQ: GPRO) new product pipeline in a research report published today. Morgan Stanley commented specifically on the "commercial and financial implications of the US clinical trial data for Aptima HPV called CLEAR that will be presented this weekend...

Jefferies & Company has raised the price target on Gen-Probe (NASDAQ: GPRO) from $75 to $92 and maintains its Buy rating.

Piper Jaffray is out with its report today on Gen-Probe (NASDAQ: GPRO), raising its PT from $69 to $78. In a note to clients, Piper Jaffray writes, "Our quarterly checks suggest improving CT/NG testing volumes, with surveyed accounts describing a 2.2% sequential volume increase. For comparative...

Piper Jaffray has raised the price target on Gen-Probe (NASDAQ: GPRO) from $69 to $78 and maintains its Overweight rating.

Oppenheimer is initiating coverage of Gen-Probe Inc. (NASDAQ: GPRO) with a Perform rating and $71 price target. “GPRO is a pioneering molecular diagnostics company on the verge of an exciting product cycle with both menu expansion and a new instrument launch,” Oppenheimer writes. “GPRO is expecting...

Piper Jaffray is providing a “positive update” on Overweight-rated Gen-Probe Inc. (NASDAQ: GPRO) following its meetings with management. “Although early in the EU panther launch, management appeared pleased with adoption thus far,” Piper Jaffray writes. “On the menu side, we believe Trich could...

Piper Jaffray has published a research report on Medical Diagnostics, writing "Our positive 4Q10 STD channel checks suggest a combination of a deductible flush and easier H1N1 comps in December. Not surprisingly, there is concern about the effect of resetting deductibles on 1Q11 trends. We believe...

Piper Jaffray has upgraded Gen-Probe (NasdaqGS: GPRO) to an Overweight rating according to their research report published today. Piper Jaffray writes, "We are upgrading GPRO shares to Overweight, with expectations for Gen-Probe's CT/NG business to re-accelerate as physician office visit trends...

Gen-Probe Incorporated (NASDAQ: GPRO) is expecting a challenging quarter for its clinical diagnostics business, according to Piper Jaffray, which states: "Based on the derivation between our channel checks and Gen-Probe's recent results, we estimate the OUS CT/NG business is now annualizing at...